目的 探讨非瓣膜性房颤患者达比加群血药浓度的影响因素及临床意义,评价血药浓度对达比加群酯出血事件的预测能力。方法 分析143例达比加群稳态血药谷浓度监测结果,采用t检验分析年龄、性别、肌酐清除率(Ccr)、合并用药对达比加群血药浓度的影响;运用受试者工作特征曲线(ROC)分析评估达比加群血药浓度对出血事件的预测能力。结果 143例患者达比加群血药浓度受年龄、性别、Ccr影响(P<0.05),与活化部分凝血活酶时间(APTT)呈正相关;25例患者发生小出血,APTT、Ccr和血药浓度与出血事件有相关性(P<0.05),血药浓度预测出血事件的ROC曲线下面积为0.909(P<0.001),曲线中Youden指数最大(0.713)时对应的最佳临界值为154.35 ng·mL-1,灵敏度和特异度分别为84%和87%,优于Ccr。结论 非瓣膜性房颤患者达比加群血药浓度临床个体差异较大,且血药浓度对出血事件预测灵敏度和特异性高,可为临床个体化用药和安全用药提供指导。
Abstract
OBJECTIVE To explore the influencing factors and clinical significance of dabigatran concentration in patients with non-valvular atrial fibrillation, and to evaluate the predictive ability of dabigatran concentration on hemorrhage events. METHODS Analysis was performed on results of 143 cases with steady-state dabigatran concentration monitoring, T-test was used to analyze the effects of age, gender, creatinine clearance rate(Ccr) and combined drugs on the blood concentration of dabigatran. The ability of dabigatran concentration predicting hemorrhage risk was assessed by ROC curve. RESULTS In 143 patients, age, sex and creatinine clearance had significant effects on the blood concentration of dabigatran(P<0.05), which was positively correlated with APTT. Small hemorrhage events occurred in 25 patients. APTT, Ccr and blood drug concentration were correlated with hemorrhage events (P<0.05). The dabigatran concentration demonstrated good discrimination performance for prediction in hemorrhage events at the best cut-off value of 154.35 ng·mL-1, the sensitivity and specificity to predict hemorrhage events were 84% and 87%, respectively. The Youden index for the cut-off value was the highest(0.713), which was better than Ccr. CONCLUSION The concentration of dabigatran in patients with non-valvular atrial fibrillation has great clinical individual differences, and has high sensitivity and specificity in predicting hemorrhage events,it can provide guidance for clinical individualized and safe medication.
关键词
达比加群 /
血药浓度监测 /
出血
{{custom_keyword}} /
Key words
dabigatran /
serum concentration monitoring /
hemorrhage
{{custom_keyword}} /
中图分类号:
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] JANUARY C T, WANN L S, ALPERT J S, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 2014, 64(21):e1-e76
[2] KIRCHHOF P, BENUSSI S, KOTECHA D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016,18(11): 1609-1678.
[3] XU L, YANG W H. Research progress on the safety of dabigatran etexilate in anticoagulant therapy. World Clin Drug(世界临床药物), 2016, 37(11):781-785.
[4] ZHAO Z N, ZHU Y C, LIANG L, et al. Meta-analysis of the efficacy and safety of uninterrupted NOACs in patients undergoing atrial fibrillation catheter ablation. Chin Pharm J(中国药学杂志), 2019, 54(10): 819-822.
[5] XU L, YANG W H, CHEN B. Determination of dabigatran concentration in plasma by LC-MS/MS and its application in anticoagulant therapy for atrial fibrillation ablation. Chin J Clin Pharm (中国临床药学杂志), 2018, 27(4):20-24.
[6] ZHANG F Y, LOU P C, WENG Y. Comparison of glomerular filtration rate and endogenous creatinine clearance estimated by creatinine formula . Prev Med(预防医学), 2017, 29(6):646-648.
[7] Chinese Expert Group on Clinical application of rivaroxaban. Expert advice on clinical application of Rivaroxaban in China- stroke prevention volume in non-valvular atrial fibrillation . Chin J Intern Med(中华内科杂志), 2013, 52(10):897-902
[8] XU L. Study on TDM monitoring, hemorrhage risk and thrombosis risk of dabigatran etexilatein NVAF patients for atrial fibrillation ablation in China. Shanghai: Shanghai Jiao Tong University,2018.
[9] REILLY P, LEHR T, HAERTTER S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol, 2014, 63(4):321-328.
[10] LEHR T, HAERTTER S, LIESENFELD K, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol, 2012, 52(9):1373- l378.
[11] HUISMAN M, LIP G, DIENER H, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost, 2012, 107(5):838-847.
[12] STANGIER J, STAHLE H, RATHGEN K, et al. Pharmacokinetics and pharmacodynamics of dabigatranetexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol, 2012, 52(2):243-250.
[13] GAO H, REN J, MEN J L. Once confused -laboratory monitoring of dabigatran ester therapy. Chin J Clin Lab Sci(临床检验杂志), 2019(11):806-809.
[14] YANG T, CHU Y J, WANG X J, et al. Bibliometric analysis of blood concentration monitoring research in China . Chin J Mod Appl Pharm(中国现代应用药学), 2021, 38(2):212-217.
[15] DOUXFILS, AGENO W, SAMAMA C, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost, 2018, 16(2):209-219.
[16] SALMONSON T, DOGNÉ J M, JANSSEN H, et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from aworrkshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother, 2017, 3(1):42-47.
[17] GOSSELIN R, ADCOCK D, BATES S, et al. International council for stand-ardization in Haematology ( ICSH) recommenidations for laboratory measurement of direct oral anticoagulants. Thromb Haemost, 2018, 118(3):437-450.
[18] BROWN K, ZAHIR H, GMOSSO M, et al. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. Crit Care, 2016, 20(1):273. Doi: 10.1186/s13054-016-1422-2.
[19] LIPPI G, FAVALORO E, MATTIUZZI C. Combined administration of anti-biotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? . Semin Thromb Hemost, 2014, 40(7):756-765.
[20] RATZINGER F, LANG M, BELIK S, et al. Lupus-anticoagulant testing at NOAC trough levels . Thomb Haemost, 2016, 116 (2):235-240.
[21] FLIEDER T, WEISER M, ELLER T, et al. Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants . Thromb Res, 2018, 165: 101-106.
[22] AIC′ A, MARJANOVIC′ D, MIRAT J, et al. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. Per Med, 2018, 15(3):209-221.
[23] WOODAHL E, HO R. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab, 2004, 5(1):11-19.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
云南省医学中心重点项目资助(FZX2019-06-01,2022YFKY010);云南省阜外心血管病医院院级科研基金项目资助(2019YFKT-08);吴阶平医学基金会项目资助(320.6750.2020-04-36)
{{custom_fund}}